This inventor holds 2 USPTO granted patents and 10 published patent applications. Top assignee: Alnylam Pharmaceuticals, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Bret Lee Bostwick: Inventor in RNA Interference Therapeutics
Introduction
Bret Lee Bostwick is an inventor associated with Cambridge, Massachusetts, and Alnylam Pharmaceuticals, Inc. His patent work includes RNA interference (RNAi) agent compositions and methods of use. The supplied information lists 2 patents.
Latest Patents
Bostwick’s listed patents concern RNAi agents targeting two genes:
- “Huntingtin (HTT) iRNA Agent Compositions and Methods of Use Thereof.”
- “Alpha-2A Adrenergic Receptor (ADRA2A) iRNA Agent Compositions and Methods of Use Thereof.”
These titles describe inventions involving RNAi compositions and their potential methods of use.
Career Highlights
Bostwick is associated with Alnylam Pharmaceuticals, Inc., a company focused on RNAi-based medicines. His listed patent work reflects research and development in gene-targeting therapeutic approaches.
Collaborations
The supplied information identifies Adam Castoreno and James D. McIninch as Bostwick’s coworkers. Their names indicate professional connections, though the information provided does not specify particular joint projects or patent contributions.
Conclusion
Bret Lee Bostwick’s listed inventions focus on RNAi agents targeting HTT and ADRA2A, connecting his patent record with Alnylam Pharmaceuticals’ work in RNAi therapeutics.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile